Carnevale, J. et al. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature 609, 174–182 (2022).
Freitas, K. A. et al. Enhanced T cell effector activity by targeting the Mediator kinase module. Science 378, eabn5647 (2022).
Brudno, J. N., Maus, M. V. & Hinrichs, C. S. CAR T cells and T-cell therapies for cancer: a translational science review. JAMA 332, 1924–1935 (2024).
Du, B. et al. CAR-T therapy in solid tumors. Cancer Cell 43, 665–679 (2025).
Anderson, K. G., Stromnes, I. M. & Greenberg, P. D. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell 31, 311–325 (2017).
Arner, E. N. & Rathmell, J. C. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell 41, 421–433 (2023).
Shifrut, E. et al. Genome-wide CRISPR screens in primary human T cells reveal key regulators of immune function. Cell 175, 1958–1971.e15 (2018).
Belk, J. A. et al. Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. Cancer Cell 40, 768–786.e7 (2022).
Knudsen, N. H. et al. In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma. Nature 646, 953–962 (2025).
Datlinger, P. et al. Systematic discovery of CRISPR-boosted CAR T cell immunotherapies. Nature 646, 963–972 (2025).
Wei, J. et al. Targeting Regnase-1 programs long-lived effector T cells for cancer therapy. Nature 576, 471–476 (2019).
Siska, P. J. et al. Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. JCI Insight 2, e93411 (2017).
Klysz, D. D. et al. Inosine induces stemness features in CAR-T cells and enhances potency. Cancer Cell 42, 266–282.e8 (2024).
Sutra Del Galy, A. et al. In vivo genome-wide CRISPR screens identify SOCS1 as intrinsic checkpoint of CD4+ TH1 cell response. Sci. Immunol. 6, eabe8219 (2021).
Si, J. et al. Hematopoietic progenitor kinase 1 (HPK1) mediates T cell dysfunction and is a druggable target for T cell-based immunotherapies. Cancer Cell 38, 551–566.e11 (2020).
Morotti, M. et al. PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function. Nature 629, 426–434 (2024).
Luo, C. et al. Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells. Immunity 58, 745–765.e9 (2025).
Lacher, S. B. et al. PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells. Nature 629, 417–425 (2024).
Wang, B. & Bian, Q. SATB1 prevents immune cell infiltration by regulating chromatin organization and gene expression of a chemokine gene cluster in T cells. Commun. Biol. 7, 1304 (2024).
Verdeil, G. MAF drives CD8+ T-cell exhaustion. Oncoimmunology 5, e1082707 (2016).
Kim, Y. J. et al. The transcription factor Mef2d regulates B:T synapse-dependent GC-TF differentiation and IL-21-mediated humoral immunity. Sci. Immunol. 8, eadf2248 (2023).
Giordano, M. et al. The tumor necrosis factor α-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells. Proc. Natl Acad. Sci. USA 111, 11115–11120 (2014).
Szeto, A. C. H. et al. Mef2d potentiates type-2 immune responses and allergic lung inflammation. Science 384, eadl0370 (2024).
Dahabieh, M. S. et al. The prostacyclin receptor PTGIR is a NRF2-dependent regulator of CD8+ T cell exhaustion. Nat. Immunol. 26, 1139–1151 (2025).
Pham, T. H., Okada, T., Matloubian, M., Lo, C. G. & Cyster, J. G. S1P1 receptor signaling overrides retention mediated by Gαi-coupled receptors to promote T cell egress. Immunity 28, 122–133 (2008).
Arnon, T. I. et al. GRK2-dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction to blood. Science 333, 1898–1903 (2011).
Muppidi, J. R., Lu, E. & Cyster, J. G. The G protein-coupled receptor P2RY8 and follicular dendritic cells promote germinal center confinement of B cells, whereas S1PR3 can contribute to their dissemination. J. Exp. Med. 212, 2213–2222 (2015).
Muppidi, J. R. et al. Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma. Nature 516, 254–258 (2014).
Feig, C. et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl Acad. Sci. USA 110, 20212–20217 (2013).
McCandless, E. E., Zhang, B., Diamond, M. S. & Klein, R. S. CXCR4 antagonism increases T cell trafficking in the central nervous system and improves survival from West Nile virus encephalitis. Proc. Natl Acad. Sci. USA 105, 11270–11275 (2008).
Kabashima, K. et al. Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat. Med. 9, 744–749 (2003).
Lu, E., Wolfreys, F. D., Muppidi, J. R., Xu, Y. & Cyster, J. G. S-geranylgeranyl-L-glutathione is a ligand for human B cell-confinement receptor P2RY8. Nature 567, 244–248 (2019).
Gallman, A. E. et al. Abcc1 and Ggt5 support lymphocyte guidance through export and catabolism of S-geranylgeranyl-l-glutathione. Sci. Immunol. 6, eabg1101 (2021).
Jung, I. Y. et al. CRISPR/Cas9-mediated knockout of DGK improves antitumor activities of human T cells. Cancer Res. 78, 4692–4703 (2018).
Wang, H. et al. Cbl-b inhibition improves manufacturing efficiency and antitumoral efficacy of anti-CD19 CAR-T cells. Int. Immunopharmacol. 147, 113971 (2025).
Schmidt, R. et al. CRISPR activation and interference screens decode stimulation responses in primary human T cells. Science 375, eabj4008 (2022).
Postler, T. S. A most versatile kinase: the catalytic subunit of PKA in T-cell biology. Int. Rev. Cell Mol. Biol. 361, 301–318 (2021).
Zhang, M. et al. G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery. Signal Transduct. Target. Ther. 9, 88 (2024).
Wu, V. H. et al. The GPCR-Gαs-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure. Nat. Immunol. 24, 1318–1330 (2023).
Ben Nasr, M. et al. Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule. Cell Metab. 36, 1302–1319.e12 (2024).
Zeng, S. et al. Local TSH/TSHR signaling promotes CD8+ T cell exhaustion and immune evasion in colorectal carcinoma. Cancer Commun. 44, 1287–1310 (2024).
Giuffrida, L. et al. CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nat. Commun. 12, 3236 (2021).
Li, S. et al. In silico and pharmacological evaluation of GPR65 as a cancer immunotherapy target regulating T-cell functions. Front. Immunol. 15, 1483258 (2024).
Qiao, G. et al. β-Adrenergic signaling blocks murine CD8+ T-cell metabolic reprogramming during activation: a mechanism for immunosuppression by adrenergic stress. Cancer Immunol. Immunother. 68, 11–22 (2019).
Nehama, D. et al. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. EBioMedicine 47, 33–43 (2019).
Vitanza, N. A. et al. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nat. Med. 31, 861–868 (2025).
Bengsch, B. et al. Epigenomic-guided mass cytometry profiling reveals disease-specific features of exhausted CD8 T cells. Immunity 48, 1029–1045.e5 (2018).
Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189–1198 (2022).
Goudy, L. et al. Integrated epigenetic and genetic programming of primary human T cells. Nat. Biotechnol. https://doi.org/10.1038/s41587-025-02856-w (2025).
Barnkob, M. B. et al. Semaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells. Nat. Commun. 15, 3173 (2024).
Matas-Rico, E. et al. Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells. Cell Rep. 37, 110013 (2021).
Carlson, C. R. et al. Delineation of type I protein kinase A-selective signaling events using an RI anchoring disruptor. J. Biol. Chem. 281, 21535–21545 (2006).
Newick, K. et al. Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase A localization. Cancer Immunol. Res. 4, 541–551 (2016).
Wunderlich, M. et al. Improved multilineage human hematopoietic reconstitution and function in NSGS mice. PLoS ONE 13, e0209034 (2018).
Shindyapin, V. V. et al. Myeloid cell mobilization and recruitment by human mesothelioma in NSG-SGM3 mice. Cells 13, 2135 (2024).
Billerbeck, E. et al. Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2Rγnull humanized mice. Blood 117, 3076–3086 (2011).
Zorn, J. A. et al. Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model. Sci. Rep. 12, 3530 (2022).
Siegler, E. L. et al. Efficient gene editing of CART cells with CRISPR-Cas12a for enhanced antitumor efficacy. Blood 136, 6–7 (2020).
Tieu, V. et al. A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells. Cell 187, 1278–1295.e20 (2024).
Takacsi-Nagy, O. et al. Evolutionarily guided transcription factor design programs novel T cell states. Preprint at bioRxiv https://doi.org/10.1101/2024.11.06.622344 (2024).
